Related Experiment Video

Updated: Apr 15, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.8K

Inhibition of insulin-like growth factor receptor: end of a targeted therapy?

Rathi N Pillai1, Suresh S Ramalingam1

  • 1Winship Cancer Institute, Emory University, GA, USA.

Translational Lung Cancer Research
|March 26, 2015
PubMed

Insights

Insulin-like Growth Factor 1 (IGF-1) receptor inhibitors show limited success in non-small cell lung cancer (NSCLC) trials. Future research should identify patients who benefit from IGF-1R antagonists and develop better combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The Insulin-like Growth Factor 1 (IGF-1) signaling pathway plays a crucial role in lung cancer development and survival.
  • IGF-1 receptor (IGF-1R) activation is associated with increased cancer risk and tumorigenesis.
  • IGF-1R inhibitors have been investigated in clinical trials for various cancers.

Purpose of the Study:

  • To evaluate the efficacy of IGF-1R inhibitors in non-small cell lung cancer (NSCLC).
  • To explore the potential of IGF-1 levels as a biomarker for sensitivity to IGF-1R inhibition.
  • To identify strategies for optimizing combination therapies involving IGF-1R antagonists in NSCLC.

Main Methods:

  • Clinical trials involving IGF-1R antagonists, often in combination with chemotherapy or EGFR inhibitors.
  • Biomarker analyses of clinical trial data, focusing on IGF-1 levels.
  • Preclinical models investigating IGF-1R signaling in lung cancer.

Main Results:

  • Most clinical trials of IGF-1R antagonists in NSCLC, particularly in combination regimens, yielded disappointing results.
  • Biomarker studies suggest that IGF-1 levels may indicate sensitivity to IGF-1R inhibition.
  • Early phase studies showed some promise, but larger trials did not meet expectations.

Conclusions:

  • IGF-1R antagonists alone or in combination with standard therapies have shown limited efficacy in unselected NSCLC populations.
  • Further research is needed to identify NSCLC patients most likely to respond to IGF-1R inhibition.
  • Development of rational combination strategies and predictive biomarkers is crucial for advancing IGF-1R-targeted therapy in NSCLC.
Keywords:
Insulin-like Growth Factor 1 (IGF-1)epidermal growth factor receptor (EGFR)insulin-like growth factor 1 receptor (IGF-1R)non-small cell lung cancer (NSCLC)

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K